Active comparator: DRV/cb — Competitive Intelligence Brief

Active comparator: DRV/cb (Active comparator: DRV/cb) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor with pharmacokinetic booster. Area: Infectious Disease.

marketed HIV protease inhibitor with pharmacokinetic booster HIV protease Infectious Disease Small molecule

Target snapshot

Active comparator: DRV/cb (Active comparator: DRV/cb) — Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. DRV/c (darunavir boosted with cobicistat) is a protease inhibitor combined with a pharmacokinetic booster that blocks HIV protease to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active comparator: DRV/cb TARGET	Active comparator: DRV/cb	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	marketed	HIV protease inhibitor with pharmacokinetic booster	HIV protease
Continue Ritonavir-boosted PI+Rosuvastatin	Continue Ritonavir-boosted PI+Rosuvastatin	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + statin)	HIV protease (PI component); HMG-CoA reductase (rosuvastatin component)
lopinavir with ritonavir in 1:1 ratio	lopinavir with ritonavir in 1:1 ratio	Drugs for Neglected Diseases	marketed	HIV protease inhibitor	HIV protease
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Darunavir/r	Darunavir/r	Juan A. Arnaiz	marketed	HIV protease inhibitor	HIV protease
Lopinavir/r	Lopinavir/r	Universidade Federal do Rio de Janeiro	marketed	Protease inhibitor	HIV protease
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor with pharmacokinetic booster class)

1. Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 drug in this class
2. Janssen Scientific Affairs, LLC · 1 drug in this class